arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Zentalis Pharmaceuticals, Inc.

ZNTL

$4.22 ▼ -0.77 (-15.43%) at close

8 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Zentalis Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $303.3M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -70.9% ↘

FCF / Share $-1.74 ↗

Trailing P/E —

Price / Book 1.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-137.06M

↑ +17.4% —

FCF / Share Free cash flow per share

$-1.74

↑ +27.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	18.0% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	47.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	0.2% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	-20.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	17.4% Good ↑ Good Improving Year-over-year change in net income	43.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-23.4% Weak ↑ Weak Improving Year-over-year change in net income	-49.2% Weak ↑ Weak Improving Year-over-year change in net income	-34.7% Weak Weak Year-over-year change in net income	-158.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	27.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	24.5% Good ↑ Good Improving Year-over-year change in free cash flow	-1.3% Weak ↑ Weak Improving Year-over-year change in free cash flow	16.2% Good Good Year-over-year change in free cash flow	-20.5% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	—	-283.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1990%)	—	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	-246.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2150%)	—	—	—	—	—	—
FCF Margin (%) (%)	—	-253.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—
FCF / Net Income (x)	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-70.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-56.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-68.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-52.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-52.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-54.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-53.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-63.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-523%)	-49.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-428%)	-66.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-545%)	-54.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-464%)	—	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Net Debt (USD)	$-35.99M	$-33.90M	$-28.04M	$-43.07M	$-59.71M	$-54.95M	$-67.25M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$0.00	$0.95	$0.00	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.91	$-2.33	$-4.47	$-4.48	$-3.72	—	—	—
Free Cash Flow per Share (USD)	$-1.74	$-2.41	$-3.19	$-3.15	$-3.75	$-3.12	—	—
Book Value per Share (USD)	$3.13	$4.73	$6.18	$7.32	—	—	—	—
Tangible Book Value per Share (USD)	$3.13	$4.73	$6.13	$7.25	—	—	—	—
Basic Weighted Avg Shares (shares)	71.87M	71.08M	65.41M	52.86M	42.69M	28.11M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$216.63M	$333.34M	$427.35M	$395.29M	$306.83M	$316.50M	$53.99M	—
Total Equity (USD)	$216.20M	$337.19M	$437.28M	$433.80M	—	—	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$67.42M	$0.00	—	—	—	—	—
Depreciation Expense (USD)	$739.00K	$1.29M	$1.39M	$1.43M	$544.00K	$160.00K	$111.00K	—
Net Income, GAAP (USD)	$-137.06M	$-165.84M	$-292.19M	$-236.81M	$-158.72M	$-117.84M	$-45.66M	—
Operating Cash Flow (USD)	$-125.25M	$-170.86M	$-207.82M	$-163.75M	$-154.09M	$-86.83M	$-39.14M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters

Zentalis Pharmaceuticals, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ZNTL with peers